Ekso BionicsEKSO
EKSO
About: Ekso Bionics Holdings Inc designs, develops and sells exoskeleton technology used in healthcare and industrial markets. The wearable exoskeletons are to be worn over clothes and controlled by a trained operator to augment human strength, endurance, and mobility. The company's segments are Enterprise Health and Personal Health. All of the company's operations are held in the United States. The regions the company operates in are the Americas, EMEA, and APAC.
Employees: 66
0
Funds holding %
of 7,324 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 5
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
12% more funds holding
Funds holding: 33 [Q4 2024] → 37 (+4) [Q1 2025]
3.12% less ownership
Funds ownership: 18.36% [Q4 2024] → 15.25% (-3.12%) [Q1 2025]
38% less capital invested
Capital invested by funds: $2.46M [Q4 2024] → $1.53M (-$939K) [Q1 2025]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$9.50
173%
upside
Avg. target
$35
899%
upside
High target
$60
1,624%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
Lake Street Ben Haynor | 173%upside $9.50 | Buy Maintained | 29 Jul 2025 |
HC Wainwright & Co. Swayampakula Ramakanth | 1,624%upside $60 | Buy Maintained | 6 May 2025 |
Financial journalist opinion
Based on 6 articles about EKSO published over the past 30 days
Neutral
Seeking Alpha
3 days ago
Ekso Bionics Holdings, Inc. (EKSO) Q2 2025 Earnings Call Transcript
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO ) Q2 2025 Earnings Conference Call July 28, 2025 4:30 PM ET Company Participants Jerome Wong - CFO & Corporate Secretary Scott G. Davis - CEO & Director Stephen Kilmer - Corporate Participant Conference Call Participants Benjamin Charles Haynor - Lake Street Capital Markets, LLC, Research Division Swayampakula Ramakanth - H.C.
Negative
Zacks Investment Research
3 days ago
Ekso Bionics (EKSO) Reports Q2 Loss, Misses Revenue Estimates
Ekso Bionics (EKSO) came out with a quarterly loss of $1.24 per share versus the Zacks Consensus Estimate of a loss of $1.2. This compares to a loss of $1.95 per share a year ago.
Neutral
The Motley Fool
3 days ago
Ekso Revenue Falls 58 Percent in Q2
Ekso Revenue Falls 58 Percent in Q2
Neutral
GlobeNewsWire
3 days ago
Ekso Bionics Reports Second Quarter 2025 Financial Results
SAN RAFAEL, Calif., July 28, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today reported financial results for the three and six months ended June 30, 2025.
Neutral
GlobeNewsWire
1 week ago
Ekso Bionics to Report Second Quarter 2025 Financial Results on July 28 – Conference Call to Follow
SAN RAFAEL, Calif., July 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it will release financial and business results for the second quarter of 2025 after the close of trading on Monday, July 28, 2025. Management will host a conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET to review the financial results and discuss recent business developments.
Neutral
GlobeNewsWire
1 week ago
Virtual eksoUniversity to Support Continuing Education of PTs and PTAs Across the Country
SAN RAFAEL, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, is pleased to announce the launch of eksoUniversity, a new platform providing continuing education courses to physical therapists (“PTs”) and physical therapy assistants (“PTAs”) across the country.
Neutral
GlobeNewsWire
1 month ago
Ekso Bionics' Acceptance into NVIDIA Connect Program Bears Early Fruit
AI voice agent for user interface being designed to support exoskeleton device operation, motivation, training, and safety First proof-of-concept demonstration comes just over a month after Company announced its acceptance into the NVIDIA Connect Program SAN RAFAEL, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (Nasdaq: EKSO) (“Ekso Bionics” or the “Company”), an industry leader in exoskeleton technology for medical and industrial use, today announced that it has successfully demonstrated initial proof-of-concept in integrating artificial intelligence (“AI”)-enabled capabilities across its portfolio of Enterprise Health and Personal Health exoskeleton devices.
Neutral
GlobeNewsWire
2 months ago
Ekso Bionics Announces New Effective Date of Reverse Stock Split
SAN RAFAEL, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it has updated the effective date of its reverse stock split of shares of its common stock at a ratio of 1-for-15 to June 2, 2025 at 12:01 a.m., Pacific time, rather than the previously disclosed effective date of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on June 2, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.
Neutral
GlobeNewsWire
2 months ago
Ekso Bionics Announces Reverse Stock Split
SAN RAFAEL, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Ekso Bionics Holdings, Inc. (the “Company”) (Nasdaq: EKSO), a leading developer of exoskeletons for medical and industrial use, today announced that it will effect a reverse stock split of shares of its common stock at a ratio of 1-for-15, effective as of May 27, 2025 at 12:01 a.m. Pacific time. The Company's common stock will open for trading on The Nasdaq Capital Market on May 27, 2025 on a split-adjusted basis under the existing symbol “EKSO”. The Company's common stock will trade under a new CUSIP number 282644 400 upon the effectiveness of the reverse stock split.
Neutral
GlobeNewsWire
2 months ago
Ekso Bionics Accepted into NVIDIA Connect Program
Company unveils a strategic initiative to build the world's first known foundation model for human motion in physical rehabilitation
Charts implemented using Lightweight Charts™